Business Wire

NEEDHAM, Mass.--(BUSINESS WIRE)-- SharkNinja, Inc. (NYSE: SN), a global product design and technology company, is pleased to announce that David Beckham has joined forces with the Ninja brand as a global brand ambassador. Known for his skills in the kitchen, passion for cooking and commitment to exceptional performance, Beckham will work closely with the Ninja team to build awareness for their innovative and user-friendly appliances.

This press release features... (continue reading...)

ZHENGZHOU, China--(BUSINESS WIRE)-- In central China’s Zhengzhou city, visiting museums has become a new trend of urban lifestyle. On May 18th, the International Museum Day, museums in Zhengzhou of Henan Province unveiled new exhibitions such as Treasures of Cultural Heritages from Luxembourg, Xu Hongfei Sculpture World Tour · Zhengzhou and fashion art photography exhibition.

This press release features multimedia. View the full release here: ... (continue reading...)

• Mollie Pearce, star of the UK reality TV show ‘The Traitors’ who was diagnosed with ulcerative colitis (UC), a type of inflammatory bowel disease (IBD), at the age of 11, partners with Celltrion to launch a new campaign.
• World IBD Day 2024 sees Celltrion launch the second installation of the Where’s Crohn’s & Colitis (CC)? campaign, focused on global inequalities in access to IBD care and treatment.
• Mollie shares her experiences with UC to highlight the... (continue reading...)

LITTLE ROCK, Ark.--(BUSINESS WIRE)-- Dillard’s, Inc. (NYSE: DDS) (the “Company” or “Dillard’s”) announced that the Board of Directors declared a cash dividend of $0.25 per share on the Class A and Class B Common Stock of the Company. The dividend is payable August 5, 2024 to shareholders of record as of June 28, 2024.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240518378250/en/

Julie J. Guymon, C.P.A. 501-376-5965 ... (continue reading...)

- 70% of Patients Receiving Seladelpar 10mg Achieved the Clinically Meaningful Composite Endpoint and 37% Achieved ALP Normalization at 12 Months -

- Reduction in Patient-Reported Pruritus (Itching) was Rapid and Durable in Patients with Moderate to Severe Symptoms -

- Positive Interim Results are Highly Consistent with Results from the Phase 3 RESPONSE Study of Seladelpar -

FOSTER CITY, Calif.--(BUSINESS WIRE)-- Gilead Sciences, Inc. (Nasdaq: GILD),... (continue reading...)